60,511 XNYS Volume
XNYS 20 Mar, 2025 10:03 AM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Kevin O'Byrne | Director | Purchase of securities on an exchange or from another person at price $ 80.44 per share. | 05 Mar 2025 | 6,500 | 6,500 (0%) | 0% | 80.4 | 522,833 | Common Stock |
| Jon Erik Fyrwald | Director, CEO | Purchase of securities on an exchange or from another person at price $ 80.24 per share. | 04 Mar 2025 | 25,000 | 29,300 (0%) | 0% | 80.2 | 2,005,878 | Common Stock |
| Michael DeVeau | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 101 | 8,252 (0%) | 0% | 0 | Common Stock | |
| Michael DeVeau | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.79 per share. | 04 Mar 2025 | 42 | 8,210 (0%) | 0% | 79.8 | 3,351 | Common Stock |
| Deborah Borg | EVP, Chief Ppl&Culture Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.79 per share. | 04 Mar 2025 | 123 | 23,379 (0%) | 0% | 79.8 | 9,814 | Common Stock |
| Deborah Borg | EVP, Chief Ppl&Culture Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 269 | 23,502 (0%) | 0% | 0 | Common Stock | |
| Simon Herriott | Pres. Health & Bioscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.79 per share. | 04 Mar 2025 | 86 | 10,755 (0%) | 0% | 79.8 | 6,862 | Common Stock |
| Simon Herriott | Pres. Health & Bioscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 237 | 10,841 (0%) | 0% | 0 | Common Stock | |
| Jennifer Amy Johnson | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.79 per share. | 04 Mar 2025 | 77 | 7,280 (0%) | 0% | 79.8 | 6,144 | Common Stock |
| Jennifer Amy Johnson | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 186 | 7,357 (0%) | 0% | 0 | Common Stock | |
| Angela Strzelecki | President, Pharma Solutions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 96 | 8,635 (0%) | 0% | 0 | Common Stock | |
| Angela Strzelecki | President, Pharma Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.79 per share. | 04 Mar 2025 | 34 | 8,601 (0%) | 0% | 79.8 | 2,713 | Common Stock |
| Ana Paula Teles de Mendonca | President, Scent | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.80 per share. | 04 Mar 2025 | 15 | 936 (0%) | 0% | 79.8 | 1,197 | Common Stock |
| Ana Paula Teles de Mendonca | President, Scent | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 35 | 951 (0%) | 0% | 0 | Common Stock | |
| Cynthia T. Jamison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 604 | 604 | - | - | Restricted Stock Units | |
| Vincent J. Intrieri | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 604 | 604 | - | - | Restricted Stock Units | |
| Mehmood Khan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 604 | 604 | - | - | Restricted Stock Units | |
| Beril Yildiz | CAO, SVP & Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 3,976 | 5,911 (0%) | 0% | 0 | Common Stock | |
| Beril Yildiz | CAO, SVP & Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.17 per share. | 15 Jan 2025 | 1,340 | 4,571 (0%) | 0% | 84.2 | 112,788 | Common Stock |
| Andres Roberto Muller | President, Food Ingredients | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 5,476 | 5,476 | - | - | Restricted Stock Units | |
| Ralf Finzel | EVP, Global Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 5,387 | 9,622 (0%) | 0% | 0 | Common Stock | |
| Finzel Ralf | EVP, Global Operations Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 91.27 per share. | 02 Dec 2024 | 1,943 | 7,679 (0%) | 0% | 91.3 | 177,338 | Common Stock |
| Finzel Ralf | EVP, Global Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 5,387 | 19,379 | - | - | Restricted Stock Units | |
| Yuvraj Arora | President, Nourish | Sale of securities on an exchange or to another person at price $ 91.76 per share. | 11 Nov 2024 | 5,000 | 3,238 (0%) | 0% | 91.8 | 458,775 | Common Stock |
| Beril Yildiz | CAO, SVP & Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.63 per share. | 03 Oct 2024 | 389 | 1,935 (0%) | 0% | 100.6 | 39,145 | Common Stock |
| Beril Yildiz | CAO, SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2024 | 1,078 | 8,127 | - | - | Restricted Stock Units | |
| Beril Yildiz | CAO, SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2024 | 1,078 | 2,324 (0%) | 0% | 0 | Common Stock | |
| Glenn R. Richter | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 11,812 | 32,171 (0%) | 0% | 0 | Common Stock | |
| Glenn R. Richter | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 11,812 | 20,392 | - | - | Restricted Stock Units | |
| Glenn R. Richter | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.12 per share. | 01 Oct 2024 | 5,122 | 27,049 (0%) | 0% | 103.1 | 528,181 | Common Stock |
| Deborah Borg | EVP, Chief HR and D&I Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 11,506 | 27,981 (0%) | 0% | 0 | Common Stock | |
| Deborah Borg | EVP, Chief HR and D&I Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 11,506 | 29,090 | - | - | Restricted Stock Units | |
| Deborah Borg | EVP, Chief HR and D&I Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 2,301 | 40,596 | - | - | Restricted Stock Units | |
| Deborah Borg | EVP, Chief HR and D&I Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.58 per share. | 03 Sep 2024 | 5,874 | 23,233 (0%) | 0% | 103.6 | 608,429 | Common Stock |
| Deborah Borg | EVP, Chief HR and D&I Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.58 per share. | 03 Sep 2024 | 1,175 | 29,107 (0%) | 0% | 103.6 | 121,707 | Common Stock |
| Deborah Borg | EVP, Chief HR and D&I Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 2,301 | 30,282 (0%) | 0% | 0 | Common Stock | |
| Simon Herriott | Pres. Health & Bioscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jul 2024 | 627 | 10,759 (0%) | 0% | 0 | Common Stock | |
| Simon Herriott | Pres. Health & Bioscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 95.02 per share. | 03 Jul 2024 | 289 | 10,470 (0%) | 0% | 95.0 | 27,461 | Common Stock |
| Simon Herriott | Pres. Health & Bioscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jul 2024 | 627 | 12,123 | - | - | Restricted Stock Units | |
| Margarita Palau Hernandez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,543 | 1,543 | - | - | Restricted Stock Units | |
| Angela Strzelecki | President, Pharma Solutions | Sale of securities on an exchange or to another person at price $ 95.66 per share. | 13 Jun 2024 | 2,588 | 8,539 (0%) | 0% | 95.7 | 247,560 | Common Stock |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 77.16 per share. | 13 Jun 2024 | 2,588 | 11,127 (0%) | 0% | 77.2 | 199,690 | Common Stock |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 2,588 | 0 | - | - | Stock Options (right to buy) | |
| Carol Anthony Davidson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,671 | 0 | - | - | Restricted Stock Units | |
| Carol Anthony Davidson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,671 | 1,926 (0%) | 0% | 0 | Common Stock | |
| Christina A. Gold | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,671 | 0 | - | - | Restricted Stock Units | |
| Christina A. Gold | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,671 | 10,840 (0%) | 0% | 0 | Common Stock | |
| Mark J. Costa | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,671 | 0 | - | - | Restricted Stock Units | |
| Mark J. Costa | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,671 | 2,139 (0%) | 0% | 0 | Common Stock | |
| Glenn R. Richter | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.64 per share. | 03 May 2024 | 1,530 | 20,359 (0%) | 0% | 86.6 | 132,559 | Common Stock |
| Glenn R. Richter | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 4,243 | 32,204 | - | - | Restricted Stock Units | |
| Glenn R. Richter | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 4,243 | 21,889 (0%) | 0% | 0 | Common Stock | |
| Roger W. Ferguson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 2,625 | 2,625 (0%) | 0% | 0 | Common Stock | |
| Roger W. Ferguson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 2,625 | 0 | - | - | Restricted Stock Units | |
| Kevin O'Byrne | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.64 per share. | 03 May 2024 | 218 | 1,715 (0%) | 0% | 86.6 | 18,888 | Common Stock |
| Kevin O'Byrne | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,671 | 0 | - | - | Restricted Stock Units | |
| Kevin O'Byrne | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,671 | 1,933 (0%) | 0% | 0 | Common Stock | |
| Deborah Borg | EVP, Chief HR and D&I Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,768 | 42,897 | - | - | Restricted Stock Units | |
| Deborah Borg | EVP, Chief HR and D&I Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.64 per share. | 03 May 2024 | 713 | 16,475 (0%) | 0% | 86.6 | 61,774 | Common Stock |
| Deborah Borg | EVP, Chief HR and D&I Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,768 | 17,188 (0%) | 0% | 0 | Common Stock | |
| Barry A. Bruno | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,671 | 3,205 (0%) | 0% | 0 | Common Stock | |
| Barry A. Bruno | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,671 | 0 | - | - | Restricted Stock Units | |
| Gaoxiang Hu | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,671 | 0 | - | - | Restricted Stock Units | |
| Gaoxiang Hu | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,671 | 2,105 (0%) | 0% | 0 | Common Stock | |
| Simon Herriott | Pres. Health & Bioscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.64 per share. | 03 May 2024 | 493 | 10,132 (0%) | 0% | 86.6 | 42,714 | Common Stock |
| Simon Herriott | Pres. Health & Bioscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,591 | 10,625 (0%) | 0% | 0 | Common Stock | |
| Simon Herriott | Pres. Health & Bioscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,591 | 12,750 | - | - | Restricted Stock Units | |
| Jennifer Amy Johnson | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 2,121 | 11,956 | - | - | Restricted Stock Units | |
| Jennifer Amy Johnson | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.64 per share. | 03 May 2024 | 765 | 7,171 (0%) | 0% | 86.6 | 66,280 | Common Stock |
| Jennifer Amy Johnson | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 2,121 | 7,936 (0%) | 0% | 0 | Common Stock | |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,060 | 8,868 (0%) | 0% | 0 | Common Stock | |
| Angela Strzelecki | President, Pharma Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.64 per share. | 03 May 2024 | 329 | 8,539 (0%) | 0% | 86.6 | 28,505 | Common Stock |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,060 | 6,709 | - | - | Restricted Stock Units | |
| Beril Yildiz | CAO, SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 848 | 9,205 | - | - | Restricted Stock Units | |
| Beril Yildiz | CAO, SVP & Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.64 per share. | 03 May 2024 | 342 | 1,246 (0%) | 0% | 86.6 | 29,631 | Common Stock |
| Beril Yildiz | CAO, SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 848 | 1,588 (0%) | 0% | 0 | Common Stock | |
| Ralf Finzel | EVP, Global Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,326 | 4,770 (0%) | 0% | 0 | Common Stock | |
| Ralf Finzel | EVP, Global Operations Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.64 per share. | 03 May 2024 | 535 | 4,235 (0%) | 0% | 86.6 | 46,352 | Common Stock |
| Ralf Finzel | EVP, Global Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 1,326 | 24,766 | - | - | Restricted Stock Units | |
| Yuvraj Arora | President, Nourish | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 11,538 | 11,538 (0%) | 0% | 0 | Common Stock | |
| Yuvraj Arora | President, Nourish | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 11,538 | 28,025 | - | - | Restricted Stock Units | |
| Yuvraj Arora | President, Nourish | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.64 per share. | 03 May 2024 | 3,300 | 8,238 (0%) | 0% | 86.6 | 285,912 | Common Stock |
| Ana Paula Teles de Mendonca | President, Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 726 | 0 | - | - | Restricted Stock Units | |
| Ana Paula Teles de Mendonca | President, Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 707 | 707 (0%) | 0% | 0 | Common Stock | |
| Ana Paula Teles de Mendonca | President, Scent | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.64 per share. | 03 May 2024 | 255 | 452 (0%) | 0% | 86.6 | 22,093 | Common Stock |
| Ana Paula Teles de Mendonca | President, Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 726 | 1,178 (0%) | 0% | 0 | Common Stock | |
| Ana Paula Teles de Mendonca | President, Scent | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.66 per share. | 03 May 2024 | 262 | 916 (0%) | 0% | 88.7 | 23,229 | Common Stock |
| Ana Paula Teles de Mendonca | President, Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 707 | 6,177 | - | - | Restricted Stock Units | |
| Carol Anthony Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,875 | 1,875 | - | - | Restricted Stock Units | |
| Christina A. Gold | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,875 | 1,875 | - | - | Restricted Stock Units | |
| Jon Erik Fyrwald | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 47,625 | 47,625 | - | - | Restricted Stock Units | |
| Mark J. Costa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,875 | 1,875 | - | - | Restricted Stock Units | |
| Glenn R. Richter | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 11,906 | 36,447 | - | - | Restricted Stock Units | |
| Roger W. Ferguson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 2,947 | 2,947 | - | - | Restricted Stock Units | |
| Kevin O'Byrne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,875 | 1,875 | - | - | Restricted Stock Units | |
| Dawn C. Willoughby | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,875 | 1,875 | - | - | Restricted Stock Units | |
| John F. Ferraro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,875 | 1,875 | - | - | Restricted Stock Units | |
| Deborah Borg | EVP, Chief HR and D&I Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 7,144 | 44,665 | - | - | Restricted Stock Units | |
| Kathryn Jean Boor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,875 | 1,875 | - | - | Restricted Stock Units | |
| Gaoxiang Hu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,875 | 1,875 | - | - | Restricted Stock Units | |
| Simon Herriott | Pres. Health & Bioscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 8,930 | 14,341 | - | - | Restricted Stock Units | |
| Jennifer Amy Johnson | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 8,334 | 14,077 | - | - | Restricted Stock Units | |
| Angela Strzelecki | President, Pharma Solutions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 5,209 | 7,769 | - | - | Restricted Stock Units | |
| Beril Yildiz | CAO, SVP & Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 3,572 | 7,196 | - | - | Restricted Stock Units | |
| Beril Yildiz | CAO, SVP & Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 2,857 | 10,053 | - | - | Restricted Stock Units | |
| Ralf Finzel | EVP, Global Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 5,953 | 26,092 | - | - | Restricted Stock Units | |
| Yuvraj Arora | President, Nourish | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 10,716 | 39,563 | - | - | Restricted Stock Units | |
| Ana Paula Teles de Mendonca | President, Scent | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 4,762 | 6,884 | - | - | Restricted Stock Units | |
| Simon Herriott | Pres. Health & Biosci. & Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 1,244 | 9,149 (0%) | 0% | 0 | Common Stock | |
| Simon Herriott | Pres. Health & Biosci. & Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 346 | 0 | - | - | Restricted Stock Units | |
| Simon Herriott | Pres. Health & Biosci. & Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 1,244 | 5,411 | - | - | Restricted Stock Units | |
| Simon Herriott | Pres. Health & Biosci. & Scent | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.34 per share. | 05 Apr 2024 | 386 | 9,001 (0%) | 0% | 83.3 | 32,169 | Common Stock |
| Simon Herriott | Pres. Health & Biosci. & Scent | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.34 per share. | 05 Apr 2024 | 108 | 9,387 (0%) | 0% | 83.3 | 9,001 | Common Stock |
| Simon Herriott | Pres. Health & Biosci. & Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 346 | 9,495 (0%) | 0% | 0 | Common Stock | |
| Jennifer Amy Johnson | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 622 | 5,819 (0%) | 0% | 0 | Common Stock | |
| Jennifer Amy Johnson | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 346 | 0 | - | - | Restricted Stock Units | |
| Jennifer Amy Johnson | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 622 | 5,743 | - | - | Restricted Stock Units | |
| Jennifer Amy Johnson | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.34 per share. | 05 Apr 2024 | 225 | 5,815 (0%) | 0% | 83.3 | 18,752 | Common Stock |
| Jennifer Amy Johnson | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.34 per share. | 05 Apr 2024 | 125 | 6,040 (0%) | 0% | 83.3 | 10,418 | Common Stock |
| Jennifer Amy Johnson | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 346 | 6,165 (0%) | 0% | 0 | Common Stock | |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 518 | 8,162 (0%) | 0% | 0 | Common Stock | |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 518 | 0 | - | - | Restricted Stock Units | |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 622 | 2,560 | - | - | Restricted Stock Units | |
| Angela Strzelecki | President, Pharma Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.34 per share. | 05 Apr 2024 | 193 | 7,808 (0%) | 0% | 83.3 | 16,085 | Common Stock |
| Angela Strzelecki | President, Pharma Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.34 per share. | 05 Apr 2024 | 161 | 8,001 (0%) | 0% | 83.3 | 13,418 | Common Stock |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 622 | 7,644 (0%) | 0% | 0 | Common Stock | |
| Simon Herriott | Pres. Health & Biosci. & Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 1,489 | 8,366 (0%) | 0% | 0 | Common Stock | |
| Simon Herriott | Pres. Health & Biosci. & Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 1,489 | 6,655 | - | - | Restricted Stock Units | |
| Simon Herriott | Pres. Health & Biosci. & Scent | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.37 per share. | 01 Apr 2024 | 461 | 7,905 (0%) | 0% | 86.4 | 39,817 | Common Stock |
| Jon Erik Fyrwald | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 56,250 | 56,250 | - | - | Restricted Stock Units | |
| Glenn R. Richter | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.87 per share. | 01 Mar 2024 | 46 | 17,646 (0%) | 0% | 75.9 | 3,490 | Common Stock |
| Glenn R. Richter | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 99 | 17,692 (0%) | 0% | 0 | Common Stock | |
| Frank Clyburn | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 1,324 | 33,682 | - | - | Restricted Stock Units | |
| Frank Clyburn | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 1,324 | 2,170 (0%) | 0% | 0 | Common Stock | |
| Frank Clyburn | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.88 per share. | 01 Mar 2024 | 323 | 1,847 (0%) | 0% | 75.9 | 24,509 | Common Stock |
| Simon Herriott | Pres. Health & Biosci. & Scent | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.88 per share. | 01 Mar 2024 | 104 | 6,877 (0%) | 0% | 75.9 | 7,892 | Common Stock |
| Simon Herriott | Pres. Health & Biosci. & Scent | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 286 | 6,981 (0%) | 0% | 0 | Common Stock | |
| Jennifer Amy Johnson | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 195 | 5,278 (0%) | 0% | 0 | Common Stock | |
| Jennifer Amy Johnson | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.88 per share. | 01 Mar 2024 | 81 | 5,197 (0%) | 0% | 75.9 | 6,146 | Common Stock |
| Angela Strzelecki | President, Pharma Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.88 per share. | 01 Mar 2024 | 48 | 7,022 (0%) | 0% | 75.9 | 3,642 | Common Stock |
| Angela Strzelecki | President, Pharma Solutions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 130 | 7,070 (0%) | 0% | 0 | Common Stock | |
| Angela Strzelecki | President, Pharma Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.99 per share. | 03 Jan 2024 | 478 | 6,940 (0%) | 0% | 80.0 | 38,235 | Common Stock |
| Strzelecki Angela | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2024 | 1,341 | 3,182 | - | - | Restricted Stock Units | |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2024 | 1,341 | 7,418 (0%) | 0% | 0 | Common Stock | |
| Yildiz Beril | CAO, SVP & Controller | Grant, award, or other acquisition of securities at price $ 79.92 per share. | 15 Dec 2023 | 52 | 740 (0%) | 0% | 79.9 | 4,156 | Common Stock |
| Finzel Ralf | EVP, Global Operations Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 76.78 per share. | 01 Dec 2023 | 1,943 | 3,444 (0%) | 0% | 76.8 | 149,184 | Common Stock |
| Ralf Finzel | EVP, Global Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2023 | 5,387 | 5,387 (0%) | 0% | 0 | Common Stock | |
| Ralf Finzel | EVP, Global Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2023 | 5,387 | 20,139 | - | - | Restricted Stock Units | |
| Jennifer Amy Johnson | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2023 | 1,041 | 6,365 | - | - | Restricted Stock Units | |
| Jennifer Amy Johnson | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.06 per share. | 01 Nov 2023 | 376 | 5,083 (0%) | 0% | 68.1 | 25,591 | Common Stock |
| Jennifer Amy Johnson | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2023 | 1,041 | 5,459 (0%) | 0% | 0 | Common Stock | |
| Beril Yildiz | CAO, SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2023 | 1,077 | 1,077 (0%) | 0% | 0 | Common Stock | |
| Beril Yildiz | CAO, SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2023 | 1,077 | 3,624 | - | - | Restricted Stock Units | |
| Beril Yildiz | CAO, SVP & Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.07 per share. | 03 Oct 2023 | 389 | 688 (0%) | 0% | 65.1 | 25,312 | Common Stock |
| Glenn R. Richter | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.97 per share. | 02 Oct 2023 | 6,031 | 17,593 (0%) | 0% | 66.0 | 397,865 | Common Stock |
| Glenn R. Richter | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Oct 2023 | 11,812 | 24,541 | - | - | Restricted Stock Units | |
| Glenn R. Richter | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Oct 2023 | 11,812 | 23,624 (0%) | 0% | 0 | Common Stock | |
| Deborah Borg | EVP, Chief HR and D&I Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2023 | 4,602 | 27,614 (0%) | 0% | 0 | Common Stock | |
| Deborah Borg | EVP, Chief HR and D&I Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2023 | 23,012 | 37,521 | - | - | Restricted Stock Units | |
| Deborah Borg | EVP, Chief HR and D&I Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2023 | 4,602 | 60,533 | - | - | Restricted Stock Units | |
| Deborah Borg | EVP, Chief HR and D&I Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 70.25 per share. | 01 Sep 2023 | 9,844 | 15,420 (0%) | 0% | 70.3 | 691,541 | Common Stock |
| Deborah Borg | EVP, Chief HR and D&I Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 70.25 per share. | 01 Sep 2023 | 2,350 | 25,264 (0%) | 0% | 70.3 | 165,088 | Common Stock |
| Deborah Borg | EVP, Chief HR and D&I Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2023 | 23,012 | 23,012 (0%) | 0% | 0 | Common Stock | |
| Simon Herriott | President Health & Biosciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 1,881 | 8,144 | - | - | Restricted Stock Units | |
| Yuvraj Arora | President, Nourish | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 28,847 | 28,847 | - | - | Restricted Stock Units | |
| Christophe Fauchon de Villeplee | President, Scent | Sale of securities on an exchange or to another person at price $ 86.35 per share. | 11 May 2023 | 1,972 | 9,093 (0%) | 0% | 86.3 | 170,282 | Common Stock |
| Carol Anthony Davidson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 May 2023 | 1,245 | 0 | - | - | Restricted Stock Units | |
| Carol Anthony Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 1,245 | 2,350 | - | - | Stock Equivalent Unit | |
| Christina A. Gold | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 1,245 | 9,169 (0%) | 0% | 0 | Common Stock | |
| Christina A. Gold | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 1,245 | 0 | - | - | Restricted Stock Units | |
| Roger W. Ferguson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 May 2023 | 1,245 | 0 | - | - | Restricted Stock Units | |
| Roger W. Ferguson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 1,245 | 17,754 | - | - | Stock Equivalent Unit | |
| Kevin O'Byrne | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 262 | 262 (0%) | 0% | 0 | Common Stock | |
| Kevin O'Byrne | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 262 | 0 | - | - | Restricted Stock Units | |
| Dawn C. Willoughby | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 434 | 0 | - | - | Restricted Stock Units | |
| Dawn C. Willoughby | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 434 | 434 (0%) | 0% | 0 | Common Stock | |
| John F. Ferraro | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 May 2023 | 1,245 | 0 | - | - | Restricted Stock Units | |
| John F. Ferraro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 1,245 | 8,609 | - | - | Stock Equivalent Unit | |
| Kathryn Jean Boor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 1,245 | 2,350 | - | - | Stock Equivalent Unit | |
| Kathryn Jean Boor | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 May 2023 | 1,245 | 0 | - | - | Restricted Stock Units | |
| Barry A. Bruno | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 1,245 | 1,534 (0%) | 0% | 0 | Common Stock | |
| Barry A. Bruno | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 1,245 | 0 | - | - | Restricted Stock Units | |
| Gaoxiang Hu | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 434 | 434 (0%) | 0% | 0 | Common Stock | |
| Gaoxiang Hu | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 434 | 0 | - | - | Restricted Stock Units | |
| Mark J. Costa | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2023 | 468 | 0 | - | - | Restricted Stock Units | |
| Mark J. Costa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 1,671 | 1,671 | - | - | Restricted Stock Units | |
| Mark J. Costa | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2023 | 468 | 468 (0%) | 0% | 0 | Common Stock | |
| Glenn R. Richter | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 12,729 | 36,353 | - | - | Restricted Stock Units | |
| Deborah Borg | EVP, Chief HR and D&I Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 5,304 | 65,135 | - | - | Restricted Stock Units | |
| Frank Clyburn | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 35,006 | 35,006 | - | - | Restricted Stock Units | |
| Simon Herriott | President Health & Biosciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 4,774 | 6,263 | - | - | Restricted Stock Units | |
| Jennifer Amy Johnson | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 6,365 | 7,406 | - | - | Restricted Stock Units | |
| Angela Strzelecki | President, Pharma Solutions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 3,182 | 4,523 | - | - | Restricted Stock Units | |
| Christophe Fauchon de Villeplee | President, Scent | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 4,774 | 4,774 | - | - | Restricted Stock Units | |
| Beril Yildiz | CAO, SVP & Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 2,546 | 4,701 | - | - | Restricted Stock Units | |
| Ralf Finzel | EVP, Global Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 3,978 | 25,526 | - | - | Restricted Stock Units | |
| Gregory L. Yep | EVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2023 | 2,665 | 6,501 (0%) | 0% | 0 | Common Stock | |
| Gregory L. Yep | EVP, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 91.45 per share. | 06 Apr 2023 | 733 | 5,768 (0%) | 0% | 91.5 | 67,033 | Common Stock |
| Gregory L. Yep | EVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2023 | 2,665 | 0 | - | - | Restricted Stock Units | |
| Christophe Fauchon de Villeplee | President, Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2023 | 913 | 11,065 (0%) | 0% | 0 | Common Stock | |
| Christophe Fauchon de Villeplee | President, Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2023 | 1,188 | 10,152 (0%) | 0% | 0 | Common Stock | |
| Christophe Fauchon de Villeplee | President, Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2023 | 1,188 | 0 | - | - | Purchased Restricted Stock Units | |
| Christophe Fauchon de Villeplee | President, Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2023 | 913 | 0 | - | - | Restricted Stock Units | |
| Kevin O'Byrne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 262 | 262 | - | - | Restricted Stock Units | |
| Simon Herriott | President Health & Biosciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2023 | 1,489 | 1,489 | - | - | Restricted Stock Units | |
| Simon Herriott | President Health & Biosciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2023 | 1,489 | 6,893 (0%) | 0% | 0 | Common Stock | |
| Simon Herriott | President Health & Biosciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.60 per share. | 01 Apr 2023 | 461 | 6,432 (0%) | 0% | 90.6 | 41,767 | Common Stock |
| Dawn C. Willoughby | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 434 | 434 | - | - | Restricted Stock Units | |
| Frank Clyburn | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 1,323 | 5,296 | - | - | Restricted Deferred Stock Units | |
| Frank Clyburn | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 91.64 per share. | 01 Mar 2023 | 477 | 846 (0%) | 0% | 91.6 | 43,712 | Common Stock |
| Frank Clyburn | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 1,323 | 1,323 (0%) | 0% | 0 | Common Stock | |
| Gaoxiang Hu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 434 | 434 | - | - | Restricted Stock Units | |
| Simon Herriott | President Health & Biosciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2023 | 617 | 2,978 | - | - | Restricted Stock Units | |
| Simon Herriott | President Health & Biosciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.13 per share. | 19 Feb 2023 | 177 | 5,367 (0%) | 0% | 96.1 | 17,015 | Common Stock |
| Simon Herriott | President Health & Biosciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2023 | 617 | 5,544 (0%) | 0% | 0 | Common Stock | |
| Jennifer Amy Johnson | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2023 | 708 | 1,041 | - | - | Restricted Stock Units | |
| Jennifer Amy Johnson | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.13 per share. | 19 Feb 2023 | 293 | 4,418 (0%) | 0% | 96.1 | 28,166 | Common Stock |
| Jennifer Amy Johnson | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2023 | 708 | 4,711 (0%) | 0% | 0 | Common Stock | |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2023 | 584 | 1,341 | - | - | Restricted Stock Units | |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2023 | 584 | 6,253 (0%) | 0% | 0 | Common Stock | |
| Angela Strzelecki | President, Pharma Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.13 per share. | 19 Feb 2023 | 176 | 6,077 (0%) | 0% | 96.1 | 16,919 | Common Stock |
| Mark J. Costa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 468 | 468 | - | - | Restricted Stock Units | |
| Michael L. Ducker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2023 | 2,209 | 9,877 (0%) | 0% | 0 | Common Stock | |
| Michael L. Ducker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2023 | 2,209 | 0 | - | - | Stock Equivalent Unit | |
| Francisco Fortanet | EVP, Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.11 per share. | 03 Jan 2023 | 2,229 | 20,262 (0%) | 0% | 103.1 | 229,832 | Common Stock |
| Francisco Fortanet | EVP, Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 5,254 | 22,491 (0%) | 0% | 0 | Common Stock | |
| Francisco Fortanet | EVP, Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 5,254 | 0 | - | - | Purchased Restricted Stock Units | |
| Angela Strzelecki | President, Pharma Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 105.64 per share. | 03 Jan 2023 | 487 | 5,669 (0%) | 0% | 105.6 | 51,447 | Common Stock |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 1,341 | 1,925 | - | - | Restricted Stock Units | |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 1,341 | 6,156 (0%) | 0% | 0 | Common Stock | |
| Christophe Fauchon de Villeplee | President, Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 784 | 0 | - | - | Restricted Stock Units | |
| Christophe Fauchon de Villeplee | President, Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 784 | 8,964 (0%) | 0% | 0 | Common Stock | |
| Nicolas Mirzayantz | President, Nourish | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Dec 2022 | 1,843 | 1,701 | - | - | Restricted Stock Units | |
| Nicolas Mirzayantz | President, Nourish | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Dec 2022 | 1,962 | 2,600 | - | - | Purchased Restricted Stock Units | |
| Ralf Finzel | EVP, Global Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2022 | 21,548 | 21,548 | - | - | Restricted Stock Units | |
| Dale F. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 1,807 | 27,876 | - | - | Stock Equivalent Unit | |
| Stephen Williamson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 1,178 | 10,562 | - | - | Stock Equivalent Unit | |
| Jennifer Amy Johnson | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 95.45 per share. | 01 Nov 2022 | 376 | 4,003 (0%) | 0% | 95.4 | 35,889 | Common Stock |
| Jennifer Amy Johnson | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2022 | 1,041 | 4,379 (0%) | 0% | 0 | Common Stock | |
| Jennifer Amy Johnson | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2022 | 1,041 | 1,749 | - | - | Restricted Stock Units | |
| Glenn R. Richter | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 11,812 | 23,624 | - | - | Restricted Stock Units | |
| Glenn R. Richter | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 11,812 | 11,812 (0%) | 0% | 0 | Common Stock | |
| Beril Yildiz | CAO, SVP & Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 2,155 | 2,155 | - | - | Restricted Stock Units | |
| Deborah Borg | EVP, Chief HR and D&I Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 9,205 | 55,229 | - | - | Restricted Stock Units | |
| Deborah Borg | EVP, Chief HR and D&I Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 4,602 | 59,831 | - | - | Restricted Stock Units | |
| Deborah Borg | EVP, Chief HR and D&I Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 46,024 | 46,024 | - | - | Restricted Stock Units | |
| Francisco Fortanet | EVP, Operations | Sale of securities on an exchange or to another person at price $ 125.00 per share. | 11 Aug 2022 | 10,000 | 17,237 (0%) | 0% | 125 | 1,250,000 | Common Stock |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 11 | 6,285 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 11 | 6,274 | - | - | Stock Equivalent Unit | |
| Christophe Fauchon de Villeplee | President, Scent | Sale of securities on an exchange or to another person at price $ 132.59 per share. | 01 Jun 2022 | 629 | 8,180 (0%) | 0% | 132.6 | 83,399 | Common Stock |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2022 | 10 | 6,262 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 10 | 6,251 | - | - | Stock Equivalent Unit | |
| Carol Anthony Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,245 | 1,245 | - | - | Restricted Stock Units | |
| Carol Anthony Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,089 | 1,089 | - | - | Stock Equivalent Unit | |
| Carol Anthony Davidson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 May 2022 | 1,089 | 0 | - | - | Restricted Stock Units | |
| Christina A. Gold | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 1,089 | 0 | - | - | Restricted Stock Units | |
| Christina A. Gold | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 1,089 | 7,924 (0%) | 0% | 0 | Common Stock | |
| Christina A. Gold | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,245 | 1,245 | - | - | Restricted Stock Units | |
| Francisco Fortanet | EVP, Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 4,293 | 4,293 | - | - | Purchased Restricted Stock Units | |
| Edward D. Breen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 1,089 | 1,544 (0%) | 0% | 0 | Common Stock | |
| Edward D. Breen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,245 | 1,245 | - | - | Restricted Stock Units | |
| Edward D. Breen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 1,089 | 0 | - | - | Restricted Stock Units | |
| Michael L. Ducker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,245 | 1,245 | - | - | Restricted Stock Units | |
| Michael L. Ducker | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 May 2022 | 1,089 | 0 | - | - | Restricted Stock Units | |
| Michael L. Ducker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,089 | 2,160 | - | - | Stock Equivalent Unit | |
| Nicolas Mirzayantz | President, Nourish | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 10,969 | 10,969 | - | - | Purchased Restricted Stock Units | |
| Glenn R. Richter | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 43,482 | 43,482 | - | - | Stock Settled Appreciation Rights | |
| Ilene S. Gordon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 1,089 | 2,344 (0%) | 0% | 0 | Common Stock | |
| Ilene S. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,245 | 1,245 | - | - | Restricted Stock Units | |
| Ilene S. Gordon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 1,089 | 0 | - | - | Restricted Stock Units | |
| Kare Schultz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 1,089 | 1,344 (0%) | 0% | 0 | Common Stock | |
| Kare Schultz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,245 | 1,245 | - | - | Restricted Stock Units | |
| Kare Schultz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 1,089 | 0 | - | - | Restricted Stock Units | |
| Roger W. Ferguson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,245 | 1,245 | - | - | Restricted Stock Units | |
| Roger W. Ferguson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 May 2022 | 1,089 | 0 | - | - | Restricted Stock Units | |
| Roger W. Ferguson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,089 | 16,258 | - | - | Stock Equivalent Unit | |
| Dale F. Morrison | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 May 2022 | 1,089 | 0 | - | - | Restricted Stock Units | |
| Dale F. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,957 | 1,957 | - | - | Restricted Stock Units | |
| Dale F. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,089 | 25,673 | - | - | Stock Equivalent Unit | |
| John F. Ferraro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,245 | 1,245 | - | - | Restricted Stock Units | |
| John F. Ferraro | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 May 2022 | 1,089 | 0 | - | - | Restricted Stock Units | |
| John F. Ferraro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,089 | 7,252 | - | - | Stock Equivalent Unit | |
| Stephen Williamson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,089 | 9,241 | - | - | Stock Equivalent Unit | |
| Stephen Williamson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,245 | 1,245 | - | - | Restricted Stock Units | |
| Stephen Williamson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 May 2022 | 1,089 | 0 | - | - | Restricted Stock Units | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,897 | 1,897 | - | - | Purchased Restricted Stock Units | |
| Kathryn Jean Boor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,245 | 1,245 | - | - | Restricted Stock Units | |
| Kathryn Jean Boor | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 May 2022 | 1,089 | 0 | - | - | Restricted Stock Units | |
| Kathryn Jean Boor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,089 | 1,089 | - | - | Stock Equivalent Unit | |
| Matthias Heinzel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 1,089 | 0 | - | - | Restricted Stock Units | |
| Matthias Heinzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,245 | 1,245 | - | - | Restricted Stock Units | |
| Matthias Heinzel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 1,089 | 1,344 (0%) | 0% | 0 | Common Stock | |
| Barry A. Bruno | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,245 | 1,245 | - | - | Restricted Stock Units | |
| Barry A. Bruno | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 289 | 289 (0%) | 0% | 0 | Common Stock | |
| Barry A. Bruno | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 289 | 0 | - | - | Restricted Stock Units | |
| Simon Herriott | President Health & Biosciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 2,988 | 2,988 | - | - | Purchased Restricted Stock Units | |
| Simon Herriott | President Health & Biosciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,660 | 1,660 | - | - | Restricted Stock Units | |
| Jennifer Amy Johnson | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 2,544 | 2,544 | - | - | Purchased Restricted Stock Units | |
| Jennifer Amy Johnson | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,141 | 1,141 | - | - | Restricted Stock Units | |
| Angela Strzelecki | President, Pharma Solutions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 1,258 | 1,258 | - | - | Restricted Stock Units | |
| Angela Strzelecki | President, Pharma Solutions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 503 | 503 | - | - | Purchased Restricted Stock Units | |
| Christophe Fauchon de Villeplee | President, Scent | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 3,941 | 3,941 | - | - | Purchased Restricted Stock Units | |
| Christophe Fauchon de Villeplee | President, Scent | Sale of securities on an exchange or to another person at price $ 121.68 per share. | 02 May 2022 | 630 | 8,809 (0%) | 0% | 121.7 | 76,658 | Common Stock |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2022 | 11 | 6,241 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2022 | 11 | 6,229 | - | - | Stock Equivalent Unit | |
| Francisco Fortanet | EVP, Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 5,006 | 0 | - | - | Purchased Restricted Stock Units | |
| Francisco Fortanet | EVP, Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 134.33 per share. | 01 Apr 2022 | 1,912 | 27,237 (0%) | 0% | 134.3 | 256,839 | Common Stock |
| Francisco Fortanet | EVP, Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 5,006 | 29,149 (0%) | 0% | 0 | Common Stock | |
| Nicolas Mirzayantz | President, Nourish | Payment of exercise price or tax liability using portion of securities received from the company at price $ 134.33 per share. | 01 Apr 2022 | 2,042 | 38,129 (0%) | 0% | 134.3 | 274,302 | Common Stock |
| Nicolas Mirzayantz | President, Nourish | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 4,353 | 40,171 (0%) | 0% | 0 | Common Stock | |
| Nicolas Mirzayantz | President, Nourish | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 4,353 | 0 | - | - | Purchased Restricted Stock Units | |
| Robert G. Anderson | Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 1,741 | 0 | - | - | Purchased Restricted Stock Units | |
| Robert G. Anderson | Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 1,741 | 17,371 (0%) | 0% | 0 | Common Stock | |
| Robert G. Anderson | Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 134.33 per share. | 01 Apr 2022 | 625 | 16,746 (0%) | 0% | 134.3 | 83,956 | Common Stock |
| Simon Herriott | President Health & Biosciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 2,978 | 3,595 | - | - | Restricted Stock Units | |
| Christophe Fauchon de Villeplee | President, Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 118.10 per share. | 01 Apr 2022 | 285 | 9,695 (0%) | 0% | 118.1 | 33,659 | Common Stock |
| Christophe Fauchon de Villeplee | President, Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 2,176 | 9,410 (0%) | 0% | 0 | Common Stock | |
| Christophe Fauchon de Villeplee | President, Scent | Sale or transfer of securities back to the company at price $ 134.33 per share. | 01 Apr 2022 | 256 | 9,439 (0%) | 0% | 134.3 | 34,388 | Common Stock |
| Christophe Fauchon de Villeplee | President, Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 2,176 | 0 | - | - | Purchased Restricted Stock Units | |
| Christophe Fauchon de Villeplee | President, Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 285 | 0 | - | - | Stock Settled Appreciation Rights | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2022 | 10 | 6,179 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 309 | 6,157 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 11 | 6,169 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.48 per share. | 15 Mar 2022 | 288 | 15,612 (0%) | 0% | 120.5 | 34,698 | Common Stock |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 662 | 15,900 (0%) | 0% | 0 | Common Stock | |
| Barry A. Bruno | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 289 | 289 | - | - | Restricted Stock Units | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 10 | 5,848 | - | - | Stock Equivalent Unit | |
| Simon Herriott | President Health & Biosciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2022 | 616 | 617 | - | - | Restricted Stock Units | |
| Simon Herriott | President Health & Biosciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2022 | 616 | 4,978 (0%) | 0% | 0 | Common Stock | |
| Simon Herriott | President Health & Biosciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 135.03 per share. | 19 Feb 2022 | 155 | 4,823 (0%) | 0% | 135.0 | 20,930 | Common Stock |
| Jennifer Amy Johnson | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2022 | 708 | 3,611 (0%) | 0% | 0 | Common Stock | |
| Jennifer Amy Johnson | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2022 | 708 | 2,790 | - | - | Restricted Stock Units | |
| Jennifer Amy Johnson | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 135.03 per share. | 19 Feb 2022 | 273 | 3,338 (0%) | 0% | 135.0 | 36,863 | Common Stock |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2022 | 585 | 3,266 | - | - | Restricted Stock Units | |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2022 | 585 | 5,003 (0%) | 0% | 0 | Common Stock | |
| Angela Strzelecki | President, Pharma Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 135.03 per share. | 19 Feb 2022 | 188 | 4,815 (0%) | 0% | 135.0 | 25,386 | Common Stock |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 10 | 5,839 | - | - | Stock Equivalent Unit | |
| Simon Herriott | President Health & Biosciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 525 | 4,494 (0%) | 0% | 0 | Common Stock | |
| Simon Herriott | President Health & Biosciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 525 | 1,233 | - | - | Restricted Stock Units | |
| Simon Herriott | President Health & Biosciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 132.10 per share. | 14 Feb 2022 | 132 | 4,362 (0%) | 0% | 132.1 | 17,437 | Common Stock |
| Jennifer Amy Johnson | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 366 | 3,055 (0%) | 0% | 0 | Common Stock | |
| Jennifer Amy Johnson | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 366 | 3,498 | - | - | Restricted Stock Units | |
| Jennifer Amy Johnson | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 132.10 per share. | 14 Feb 2022 | 152 | 2,903 (0%) | 0% | 132.1 | 20,079 | Common Stock |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 366 | 4,538 (0%) | 0% | 0 | Common Stock | |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 366 | 3,851 | - | - | Restricted Stock Units | |
| Angela Strzelecki | President, Pharma Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 132.10 per share. | 14 Feb 2022 | 120 | 4,418 (0%) | 0% | 132.1 | 15,852 | Common Stock |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2022 | 10 | 5,828 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 9 | 5,818 | - | - | Stock Equivalent Unit | |
| Christophe Fauchon de Villeplee | President, Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2022 | 784 | 784 | - | - | Restricted Stock Units | |
| Christophe Fauchon de Villeplee | President, Scent | Exercise or conversion of derivative security received from the company (such as an option) at price $ 149.12 per share. | 02 Jan 2022 | 784 | 7,234 (0%) | 0% | 149.1 | 116,910 | Common Stock |
| Simon Herriott | President Health & Biosciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2021 | 3,241 | 4,852 (0%) | 0% | 0 | Common Stock | |
| Simon Herriott | President Health & Biosciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2021 | 3,241 | 0 | - | - | Restricted Stock Units | |
| Simon Herriott | President Health & Biosciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 149.82 per share. | 31 Dec 2021 | 891 | 3,961 (0%) | 0% | 149.8 | 133,490 | Common Stock |
| Jennifer Amy Johnson | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2021 | 3,241 | 0 | - | - | Restricted Stock Units | |
| Jennifer Amy Johnson | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2021 | 3,241 | 3,925 (0%) | 0% | 0 | Common Stock | |
| Jennifer Amy Johnson | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 149.82 per share. | 31 Dec 2021 | 1,236 | 2,689 (0%) | 0% | 149.8 | 185,178 | Common Stock |
| Angela Strzelecki | President, Pharma Solutions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2021 | 2,682 | 4,217 | - | - | Restricted Stock Units | |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2021 | 3,481 | 0 | - | - | Stock Options (right to buy) | |
| Angela Strzelecki | President, Pharma Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 115.48 per share. | 30 Dec 2021 | 3,481 | 4,172 (0%) | 0% | 115.5 | 401,986 | Common Stock |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2021 | 82 | 64,695 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2021 | 14 | 5,776 | - | - | Stock Equivalent Unit | |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2021 | 93 | 64,613 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2021 | 9 | 5,762 | - | - | Stock Equivalent Unit | |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2021 | 80 | 64,519 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2021 | 9 | 5,753 | - | - | Stock Equivalent Unit | |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 75 | 64,438 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 8 | 5,743 | - | - | Stock Equivalent Unit | |
| Dale F. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2021 | 780 | 24,295 | - | - | Stock Equivalent Unit | |
| Stephen Williamson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2021 | 780 | 8,056 | - | - | Stock Equivalent Unit | |
| Jennifer Amy Johnson | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2021 | 2,082 | 3,864 | - | - | Restricted Stock Units | |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2021 | 78 | 64,363 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2021 | 9 | 5,734 | - | - | Stock Equivalent Unit | |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2021 | 78 | 64,285 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2021 | 9 | 5,725 | - | - | Stock Equivalent Unit | |
| Nicolas Mirzayantz | President, Nourish | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 3,544 | 3,544 | - | - | Restricted Stock Units | |
| Glenn R. Richter | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 35,436 | 35,436 | - | - | Restricted Stock Units | |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 86 | 63,835 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 10 | 5,683 | - | - | Stock Equivalent Unit | |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2021 | 79 | 63,749 | - | - | Stock Equivalent Unit | |
| Rustom Jilla | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2021 | 32 | 723 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2021 | 9 | 5,673 | - | - | Stock Equivalent Unit | |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Aug 2021 | 76 | 63,669 | - | - | Stock Equivalent Unit | |
| Rustom Jilla | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Aug 2021 | 31 | 690 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Aug 2021 | 9 | 5,663 | - | - | Stock Equivalent Unit | |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2021 | 73 | 63,593 | - | - | Stock Equivalent Unit | |
| Rustom Jilla | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2021 | 29 | 659 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2021 | 8 | 5,654 | - | - | Stock Equivalent Unit | |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jul 2021 | 76 | 63,520 | - | - | Stock Equivalent Unit | |
| Rustom Jilla | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jul 2021 | 31 | 629 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jul 2021 | 9 | 5,645 | - | - | Stock Equivalent Unit | |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 79 | 63,443 | - | - | Stock Equivalent Unit | |
| Rustom Jilla | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 17 | 598 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 9 | 5,636 | - | - | Stock Equivalent Unit | |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 77 | 63,035 | - | - | Stock Equivalent Unit | |
| Rustom Jilla | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 16 | 578 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 9 | 5,598 | - | - | Stock Equivalent Unit | |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 78 | 62,958 | - | - | Stock Equivalent Unit | |
| Rustom Jilla | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 16 | 561 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 9 | 5,589 | - | - | Stock Equivalent Unit | |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 81 | 62,880 | - | - | Stock Equivalent Unit | |
| Rustom Jilla | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 23 | 544 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 9 | 5,579 | - | - | Stock Equivalent Unit | |
| Ilene S. Gordon | Director | Purchase of securities on an exchange or from another person at price $ 140.39 per share. | 14 May 2021 | 1,000 | 1,255 (0%) | 0% | 140.4 | 140,386 | Common Stock |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 81 | 62,799 | - | - | Stock Equivalent Unit | |
| Rustom Jilla | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 16 | 520 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 9 | 5,570 | - | - | Stock Equivalent Unit | |
| Simon Herriott | President Health & Biosciences | Sale of securities on an exchange or to another person at price $ 138.47 per share. | 13 May 2021 | 1,332 | 1,514 (0%) | 0% | 138.5 | 184,442 | Common Stock |
| Simon Herriott | President Health & Biosciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2021 | 1,513 | 0 | - | - | Stock Options (right to buy) | |
| Simon Herriott | President Health & Biosciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 115.48 per share. | 13 May 2021 | 1,513 | 2,846 (0%) | 0% | 115.5 | 174,721 | Common Stock |
| John F. Ferraro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2021 | 1,047 | 6,024 | - | - | Stock Equivalent Unit | |
| John F. Ferraro | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 06 May 2021 | 1,047 | 0 | - | - | Restricted Stock Units | |
| Dale F. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,047 | 23,257 | - | - | Stock Equivalent Unit | |
| Dale F. Morrison | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2021 | 1,047 | 0 | - | - | Restricted Stock Units | |
| Dale F. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,089 | 1,089 | - | - | Restricted Stock Units | |
| John F. Ferraro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,089 | 1,089 | - | - | Restricted Stock Units | |
| Carol Anthony Davidson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2021 | 255 | 255 (0%) | 0% | 0 | Common Stock | |
| Carol Anthony Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,089 | 1,089 | - | - | Restricted Stock Units | |
| Carol Anthony Davidson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2021 | 255 | 0 | - | - | Restricted Stock Units | |
| Christina A. Gold | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2021 | 1,047 | 6,835 (0%) | 0% | 0 | Common Stock | |
| Christina A. Gold | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2021 | 1,047 | 0 | - | - | Restricted Stock Units | |
| Christina A. Gold | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,089 | 1,089 | - | - | Restricted Stock Units | |
| Francisco Fortanet | EVP, Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 3,525 | 3,525 | - | - | Purchased Restricted Stock Units | |
| Edward D. Breen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,089 | 1,089 | - | - | Restricted Stock Units | |
| Edward D. Breen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2021 | 255 | 0 | - | - | Restricted Stock Units | |
| Edward D. Breen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2021 | 255 | 455 (0%) | 0% | 0 | Common Stock | |
| Michael L. Ducker | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2021 | 1,047 | 0 | - | - | Restricted Stock Units | |
| Michael L. Ducker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,089 | 1,089 | - | - | Restricted Stock Units | |
| Michael L. Ducker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,047 | 1,047 | - | - | Stock Equivalent Unit | |
| Nicolas Mirzayantz | Group President Fragrance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 4,562 | 4,562 | - | - | Purchased Restricted Stock Units | |
| Ilene S. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,089 | 1,089 | - | - | Restricted Stock Units | |
| Ilene S. Gordon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2021 | 255 | 255 (0%) | 0% | 0 | Common Stock | |
| Ilene S. Gordon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2021 | 255 | 0 | - | - | Restricted Stock Units | |
| Kare Schultz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2021 | 255 | 0 | - | - | Restricted Stock Units | |
| Kare Schultz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,089 | 1,089 | - | - | Restricted Stock Units | |
| Kare Schultz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2021 | 255 | 255 (0%) | 0% | 0 | Common Stock | |
| Roger W. Ferguson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,047 | 14,827 | - | - | Stock Equivalent Unit | |
| Roger W. Ferguson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,089 | 1,089 | - | - | Restricted Stock Units | |
| Roger W. Ferguson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2021 | 1,047 | 0 | - | - | Restricted Stock Units | |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 23,657 | 23,657 | - | - | Purchased Restricted Stock Units | |
| Stephen Williamson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,047 | 7,196 | - | - | Stock Equivalent Unit | |
| Stephen Williamson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,089 | 1,089 | - | - | Restricted Stock Units | |
| Stephen Williamson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2021 | 1,047 | 0 | - | - | Restricted Stock Units | |
| Rustom Jilla | CFO | Grant, award, or other acquisition of securities at price $ 144.67 per share. | 05 May 2021 | 2,198 | 5,746 (0%) | 0% | 144.7 | 317,985 | Common Stock |
| Rustom Jilla | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 4,147 | 4,147 | - | - | Purchased Restricted Stock Units | |
| Gonzalez Susana Suarez | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,382 | 1,382 | - | - | Restricted Stock Units | |
| Gonzalez Susana Suarez | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 829 | 829 | - | - | Purchased Restricted Stock Units | |
| Gonzalez Susana Suarez | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 3,456 | 3,456 | - | - | Stock Settled Appreciation Rights | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,659 | 1,659 | - | - | Purchased Restricted Stock Units | |
| Kathryn Jean Boor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2021 | 255 | 255 (0%) | 0% | 0 | Common Stock | |
| Kathryn Jean Boor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2021 | 255 | 0 | - | - | Restricted Stock Units | |
| Kathryn Jean Boor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,089 | 1,089 | - | - | Restricted Stock Units | |
| Matthias Heinzel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2021 | 255 | 0 | - | - | Restricted Stock Units | |
| Matthias Heinzel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2021 | 255 | 255 (0%) | 0% | 0 | Common Stock | |
| Matthias Heinzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,089 | 1,089 | - | - | Restricted Stock Units | |
| Kathy Lynn Fortmann | Divisional CEO, Taste | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 3,940 | 3,940 | - | - | Restricted Stock Units | |
| Simon Herriott | President Health & Biosciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 346 | 346 | - | - | Restricted Stock Units | |
| Simon Herriott | President Health & Biosciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,244 | 1,244 | - | - | Purchased Restricted Stock Units | |
| Jennifer Amy Johnson | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 622 | 622 | - | - | Purchased Restricted Stock Units | |
| Jennifer Amy Johnson | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 346 | 346 | - | - | Restricted Stock Units | |
| Angela Strzelecki | President, Pharma Solutions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 518 | 518 | - | - | Restricted Stock Units | |
| Angela Strzelecki | President, Pharma Solutions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 622 | 622 | - | - | Purchased Restricted Stock Units | |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 161 | 62,717 | - | - | Stock Equivalent Unit | |
| Rustom Jilla | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 33 | 503 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 19 | 5,560 | - | - | Stock Equivalent Unit | |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2021 | 81 | 62,555 | - | - | Stock Equivalent Unit | |
| Rustom Jilla | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2021 | 16 | 470 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2021 | 9 | 5,541 | - | - | Stock Equivalent Unit | |
| Francisco Fortanet | EVP, Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2021 | 4,282 | 25,778 (0%) | 0% | 0 | Common Stock | |
| Francisco Fortanet | EVP, Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2021 | 4,282 | 0 | - | - | Purchased Restricted Stock Units | |
| Francisco Fortanet | EVP, Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 139.00 per share. | 02 Apr 2021 | 1,635 | 24,143 (0%) | 0% | 139 | 227,265 | Common Stock |
| Nicolas Mirzayantz | Group President Fragrance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 139.00 per share. | 02 Apr 2021 | 1,600 | 35,818 (0%) | 0% | 139 | 222,400 | Common Stock |
| Nicolas Mirzayantz | Group President Fragrance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2021 | 4,710 | 37,418 (0%) | 0% | 0 | Common Stock | |
| Nicolas Mirzayantz | Group President Fragrance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2021 | 4,710 | 0 | - | - | Purchased Restricted Stock Units | |
| Andreas Fibig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 139.00 per share. | 02 Apr 2021 | 9,407 | 77,620 (0%) | 0% | 139 | 1,307,573 | Common Stock |
| Andreas Fibig | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2021 | 21,413 | 87,027 (0%) | 0% | 0 | Common Stock | |
| Andreas Fibig | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2021 | 21,413 | 0 | - | - | Purchased Restricted Stock Units | |
| Gonzalez Susana Suarez | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2021 | 963 | 8,433 (0%) | 0% | 0 | Common Stock | |
| Gonzalez Susana Suarez | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2021 | 1,606 | 7,470 (0%) | 0% | 0 | Common Stock | |
| Gonzalez Susana Suarez | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2021 | 1,606 | 0 | - | - | Restricted Stock Units | |
| Gonzalez Susana Suarez | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2021 | 963 | 0 | - | - | Purchased Restricted Stock Units | |
| Gonzalez Susana Suarez | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 139.00 per share. | 02 Apr 2021 | 735 | 7,257 (0%) | 0% | 139 | 102,165 | Common Stock |
| Gonzalez Susana Suarez | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 139.00 per share. | 02 Apr 2021 | 441 | 7,992 (0%) | 0% | 139 | 61,299 | Common Stock |
| Robert G. Anderson | Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2021 | 1,713 | 0 | - | - | Purchased Restricted Stock Units | |
| Robert G. Anderson | Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2021 | 1,713 | 15,820 (0%) | 0% | 0 | Common Stock | |
| Robert G. Anderson | Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 139.00 per share. | 02 Apr 2021 | 582 | 15,238 (0%) | 0% | 139 | 80,898 | Common Stock |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2021 | 75 | 62,129 | - | - | Stock Equivalent Unit | |
| Rustom Jilla | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2021 | 17 | 451 | - | - | Stock Equivalent Unit | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2021 | 9 | 5,501 | - | - | Stock Equivalent Unit | |
| Francisco Fortanet | EVP, Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 136.78 per share. | 15 Mar 2021 | 74 | 21,496 (0%) | 0% | 136.8 | 10,122 | Common Stock |
| Francisco Fortanet | EVP, Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 193 | 21,570 (0%) | 0% | 0 | Common Stock | |
| Nicolas Mirzayantz | Group President Fragrance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 108 | 2,875 | - | - | Stock Equivalent Unit | |
| Nicolas Mirzayantz | Group President Fragrance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 389 | 32,896 (0%) | 0% | 0 | Common Stock | |
| Nicolas Mirzayantz | Group President Fragrance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 136.79 per share. | 15 Mar 2021 | 133 | 32,763 (0%) | 0% | 136.8 | 18,193 | Common Stock |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 49 | 62,053 | - | - | Stock Equivalent Unit | |
| Andreas Fibig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 1,944 | 62,003 | - | - | Stock Equivalent Unit | |
| Rustom Jilla | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 17 | 434 | - | - | Stock Equivalent Unit | |
| Gonzalez Susana Suarez | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 136.80 per share. | 15 Mar 2021 | 83 | 5,864 (0%) | 0% | 136.8 | 11,354 | Common Stock |
| Gonzalez Susana Suarez | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 181 | 5,947 (0%) | 0% | 0 | Common Stock | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 120 | 14,147 (0%) | 0% | 0 | Common Stock | |
| Robert G. Anderson | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 10 | 5,491 | - | - | Stock Equivalent Unit |